You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for Plinabulin


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Plinabulin?

Plinabulin is an investigational drug.

There have been 12 clinical trials for Plinabulin. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2015.

The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Neutropenia. The leading clinical trial sponsors are BeyondSpring Pharmaceuticals Inc., M.D. Anderson Cancer Center, and Memorial Sloan Kettering Cancer Center.

There are thirty US patents protecting this investigational drug and two hundred and fifty-four international patents.

Recent Clinical Trials for Plinabulin
TitleSponsorPhase
First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLCXiaorong DongPhase 2
Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)BeyondSpring Pharmaceuticals Inc.Phase 2
Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)Merck Sharp & Dohme LLCPhase 2

See all Plinabulin clinical trials

Clinical Trial Summary for Plinabulin

Top disease conditions for Plinabulin
trials01234567Lung NeoplasmsCarcinoma, Non-Small-Cell LungNeutropenia[disabled in preview]
Top clinical trial sponsors for Plinabulin
trials012345678BeyondSpring Pharmaceuticals Inc.M.D. Anderson Cancer CenterMemorial Sloan Kettering Cancer Center[disabled in preview]

See all Plinabulin clinical trials

US Patents for Plinabulin

DrugnamePatent NumberPatent TitlePatent AssigneeEstimated Expiration
Plinabulin ⤷  Subscribe Method of treating a brain tumor BeyondSpring Pharmaceuticals, Inc. (New York, NY) ⤷  Subscribe
Plinabulin ⤷  Subscribe Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Subscribe
Plinabulin ⤷  Subscribe Nanoparticle formulations for delivering multiple therapeutic agents AMRITA VISHWA VIDYAPEETHAM (Kochi, Kerala, unknown) ⤷  Subscribe
>Drugname>Patent Number>Patent Title>Patent Assignee>Estimated Expiration
Showing 1 to 3 of 3 entries

International Patents for Plinabulin

DrugnameCountryDocument NumberEstimated ExpirationRelated US Patent
Plinabulin Australia AU2016229295 2035-03-06 ⤷  Subscribe
Plinabulin Australia AU2021254549 2035-03-06 ⤷  Subscribe
Plinabulin Brazil BR112017018964 2035-03-06 ⤷  Subscribe
>Drugname>Country>Document Number>Estimated Expiration>Related US Patent
Showing 1 to 3 of 3 entries

Development Update and Market Projection for Plinabulin

Introduction to Plinabulin

Plinabulin, developed by BeyondSpring Pharmaceuticals, is a groundbreaking drug candidate that has been making significant strides in the field of oncology. It is a selective immunomodulating microtubule-binding agent (SIMBA) with a unique mechanism of action that sets it apart from other treatments.

Mechanism of Action

Plinabulin works by triggering the release of the immune defense protein GEF-H1, which has two distinct effects. First, it leads to the maturation of dendritic cells, resulting in the activation of tumor antigen-specific T-cells to target cancer cells. Second, it boosts the number of hematopoietic stem/progenitor cells (HSPCs), which is crucial for preventing chemotherapy-induced neutropenia (CIN)[1].

Clinical Development

Chemotherapy-Induced Neutropenia (CIN)

Plinabulin is the first drug candidate submitted for FDA approval that has the potential to work in the critical first week of chemotherapy, before G-CSF is effective, to prevent the onset and improve clinical outcomes of CIN. Despite receiving a Complete Response Letter from the FDA, BeyondSpring remains confident in the efficacy and safety data for plinabulin in combination with G-CSF for CIN prevention. The company plans to work closely with the FDA to consider a possible future clinical pathway, which may include a second study[1].

Non-Small Cell Lung Cancer (NSCLC)

In addition to its potential in CIN, plinabulin has shown promising results in treating NSCLC. Phase 3 studies have demonstrated significant efficacy in extending overall survival (OS) in NSCLC patients. Moreover, a Phase 2 Investigator-Initiated Trial (IIT) combining plinabulin with pembrolizumab and docetaxel in metastatic NSCLC patients who had progressed on prior immune checkpoint inhibitors (ICIs) showed a doubled median progression-free survival (PFS) of 8.6 months compared to historical controls. This combination also achieved an impressive disease control rate of almost 90%[3].

Market Projection

Neutropenia Treatment Market

The global neutropenia treatment market is expected to reach $18.9 billion by 2026, growing at a CAGR of 6.5% during the forecast period. The introduction of small molecules like plinabulin is anticipated to revolutionize the therapeutic regimen for neutropenia. Plinabulin's immune-boosting effects and lower processing costs compared to biologics make it an attractive option in a market with high demand for cost-effective treatments[2].

Cancer Therapy Market

BeyondSpring's focus on developing plinabulin as a direct anti-cancer agent in various cancer indications positions it well in the broader cancer therapy market. The company's R&D Day highlighted the potential of plinabulin in combination therapies with chemotherapy or radiation, particularly for patients who have failed prior PD-1/PD-L1 inhibitors. This expands the market potential for plinabulin beyond just CIN prevention[4].

Regulatory Status

Plinabulin has received Breakthrough Therapy designation and priority review from both the U.S. and China FDA for the CIN prevention indication. This regulatory support underscores the drug's potential to address significant unmet medical needs in cancer treatment[1].

Ongoing and Future Studies

BeyondSpring is advancing plinabulin through various IIT studies at leading institutions in the U.S. and China. Preliminary results from these studies are expected to be reported in the second half of 2024 and are anticipated to further validate plinabulin's unique mechanism of action. If these interim clinical data are positive, the company plans to explore opportunities for third-party partnerships to extend and accelerate plinabulin’s outreach[5].

Financial and Operational Updates

In 2023, BeyondSpring reported positive results, including the dosing of patients in Phase 2 trials for plinabulin and Keytruda combinations, achieving milestones in molecular glue discovery, and making key director appointments. The company's financial performance showed a decrease in R&D and G&A expenses, resulting in a net loss of $21.0 million for 2023. These developments indicate a strong operational foundation for the continued advancement of plinabulin[4].

Expert Insights

"Plinabulin is a potent inducer of dendritic cell or DC maturation that leads to T cell activation. DCs are the most potent antigen presenting cell (APC). This unique mechanism of action reinforces anti-tumor immune response with the potential to overcome acquired ICI resistance," said Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring[3].

Key Takeaways

  • Unique Mechanism of Action: Plinabulin triggers the release of GEF-H1, leading to dendritic cell maturation and HSPC boost.
  • CIN Prevention: Potential to work in the critical first week of chemotherapy to prevent CIN.
  • NSCLC Treatment: Significant efficacy in extending OS and improving PFS in NSCLC patients.
  • Market Growth: Expected to contribute to the $18.9 billion neutropenia treatment market by 2026.
  • Regulatory Support: Received Breakthrough Therapy designation and priority review from U.S. and China FDA.
  • Ongoing Studies: Various IIT studies ongoing with preliminary results expected in 2H 2024.

FAQs

  1. What is Plinabulin?

    • Plinabulin is a selective immunomodulating microtubule-binding agent (SIMBA) developed by BeyondSpring Pharmaceuticals.
  2. How does Plinabulin work?

    • Plinabulin works by triggering the release of the immune defense protein GEF-H1, leading to dendritic cell maturation and the boost of hematopoietic stem/progenitor cells (HSPCs).
  3. What are the potential indications for Plinabulin?

    • Plinabulin is being developed for the prevention of chemotherapy-induced neutropenia (CIN) and as a treatment for non-small cell lung cancer (NSCLC).
  4. What is the current regulatory status of Plinabulin?

    • Plinabulin has received Breakthrough Therapy designation and priority review from both the U.S. and China FDA for the CIN prevention indication.
  5. What are the market projections for Plinabulin?

    • Plinabulin is expected to contribute to the growing neutropenia treatment market, projected to reach $18.9 billion by 2026.

Sources

  1. BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia (CIN) - Biospace.
  2. Neutropenia Treatment Market Size, Growth & Forecast 2020-2026 - KBV Research.
  3. BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin Docetaxel in Metastatic NSCLC after Progressing on Prior - GlobeNewswire.
  4. BeyondSpring Inc. Ordinary Shares - BYSI STOCK NEWS - Stock Titan.
  5. BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics - BeyondSpring Pharmaceuticals.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.